Skip to main content
Erschienen in: International Journal of Colorectal Disease 7/2022

13.06.2022 | Original Article

Primary ovarian cancer after colorectal cancer: a Dutch nationwide population-based study

verfasst von: R. van der Meer, I. H. J. T. de Hingh, S. F. P. J. Coppus, F. N. van Erning, R. M. H. Roumen

Erschienen in: International Journal of Colorectal Disease | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Women with colorectal cancer (CRC) are at risk not only of developing ovarian metastases, but also of developing a primary ovarian malignancy. Several earlier studies have in fact shown a link between the development of primary ovarian cancer and CRC. The purpose of this study was therefore to determine the risk of developing a primary ovarian cancer in women with prior CRC compared to the general population.

Methods

Data from the Netherlands Cancer Registry were used. All women diagnosed with invasive CRC between 1989 and 2017 were included. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) per 10,000 person-years were calculated.

Results

During the study period, 410 (0.3%) CRC patients were diagnosed with primary ovarian cancer. Women with CRC had a 20% increased risk of developing ovarian cancer compared to the general population (SIR = 1.2, 95% CI: 1.1–1.3). The AER of ovarian cancer was 0.9 per 10,000 person-years. The risk was especially increased within the first year of a CRC diagnosis (SIR = 3.3, 95% CI: 2.8–3.8) and in women aged ≤ 55 years (SIR = 2.0, 95% CI: 1.6–2.6).

Conclusion

This study found a slightly increased risk of primary ovarian cancer in women diagnosed with CRC compared to the general population. However, this may be partly attributable to surveillance or detection bias. Nevertheless, our findings could be helpful for patient counseling, as CRC patients do not currently receive information concerning the increased risk of ovarian cancer.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
2.
Zurück zum Zitat Pitt J, Dawson PM (1999) Oophorectomy in women with colorectal cancer. Eur J Surg Oncol 25:432–438CrossRef Pitt J, Dawson PM (1999) Oophorectomy in women with colorectal cancer. Eur J Surg Oncol 25:432–438CrossRef
3.
Zurück zum Zitat Shin DW, Choi YJ, Kim HS, Han KD, Yoon H, Park YS, Kim N, Lee DH (2018) Secondary breast, ovarian, and uterine cancers after colorectal cancer: a nationwide population-based cohort study in Korea. Dis Colon Rectum 61:1250–1257CrossRef Shin DW, Choi YJ, Kim HS, Han KD, Yoon H, Park YS, Kim N, Lee DH (2018) Secondary breast, ovarian, and uterine cancers after colorectal cancer: a nationwide population-based cohort study in Korea. Dis Colon Rectum 61:1250–1257CrossRef
4.
Zurück zum Zitat McCredie M, Macfarlane GJ, Bell J, Coates M (1997) Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972–1991. Cancer Epidemiol Biomarkers Prev 6:155–160PubMed McCredie M, Macfarlane GJ, Bell J, Coates M (1997) Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972–1991. Cancer Epidemiol Biomarkers Prev 6:155–160PubMed
5.
Zurück zum Zitat Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) The proportion of second cancers attributable to radiotherapy treatment in adults: a prospective cohort study in the US SEER cancer registries. Lancet Oncol 12:353–360CrossRef Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) The proportion of second cancers attributable to radiotherapy treatment in adults: a prospective cohort study in the US SEER cancer registries. Lancet Oncol 12:353–360CrossRef
6.
Zurück zum Zitat Birgisson H, Påhlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131CrossRef Birgisson H, Påhlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131CrossRef
8.
Zurück zum Zitat Bian X, Xia J, Wang K, Wang Q, Yang L, Wu W, Li L (2020) The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study. J Cancer 11:6178–6187CrossRef Bian X, Xia J, Wang K, Wang Q, Yang L, Wu W, Li L (2020) The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study. J Cancer 11:6178–6187CrossRef
9.
Zurück zum Zitat Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222CrossRef Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222CrossRef
10.
Zurück zum Zitat Banerjee S, Kapur S, Moran BJ (2005) The role of prophylactic oophorectomy in women undergoing surgery for colorectal cancer. Color Dis 7:214–217CrossRef Banerjee S, Kapur S, Moran BJ (2005) The role of prophylactic oophorectomy in women undergoing surgery for colorectal cancer. Color Dis 7:214–217CrossRef
11.
Zurück zum Zitat Paramythiotis D, Goulas P, Moysidis M, Karakatsanis A, Tzioufa-Asimakopoulou V, Sotiriou S, Michalopoulos A (2019) Metachronous ovarian metastases in a patient with primary colorectal cancer. A case report and review of the literature. Am J Case Rep 20:1515–1520CrossRef Paramythiotis D, Goulas P, Moysidis M, Karakatsanis A, Tzioufa-Asimakopoulou V, Sotiriou S, Michalopoulos A (2019) Metachronous ovarian metastases in a patient with primary colorectal cancer. A case report and review of the literature. Am J Case Rep 20:1515–1520CrossRef
13.
Zurück zum Zitat Zhang X, Liu L, Song F, Song Y, Dai H (2019) Ages at menarche and menopause, and mortality among postmenopausal women. Maturitas 130:50–56CrossRef Zhang X, Liu L, Song F, Song Y, Dai H (2019) Ages at menarche and menopause, and mortality among postmenopausal women. Maturitas 130:50–56CrossRef
14.
Zurück zum Zitat Roman Lay AA, do Nascimento CF, Horta BL, Dias Porto Chiavegatto Filho A (2020) Reproductive factors and age at natural menopause: a systematic review and meta-analysis. Maturitas 131:57–64 Roman Lay AA, do Nascimento CF, Horta BL, Dias Porto Chiavegatto Filho A (2020) Reproductive factors and age at natural menopause: a systematic review and meta-analysis. Maturitas 131:57–64
15.
Zurück zum Zitat Ossewaarde ME, Bots ML, Verbeek ALM, Peeters PHM, Van Der Graaf Y, Grobbee DE, Van Der Schouw YT (2005) Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 16:556–562CrossRef Ossewaarde ME, Bots ML, Verbeek ALM, Peeters PHM, Van Der Graaf Y, Grobbee DE, Van Der Schouw YT (2005) Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 16:556–562CrossRef
16.
Zurück zum Zitat Hemminki K, Li X, Dong C (2001) Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:793–798PubMed Hemminki K, Li X, Dong C (2001) Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:793–798PubMed
17.
Zurück zum Zitat Evans HS, Møller H, Robinson D, Lewis CM, Bell CMJ, Hodgson SV (2002) The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 50:647–652CrossRef Evans HS, Møller H, Robinson D, Lewis CM, Bell CMJ, Hodgson SV (2002) The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 50:647–652CrossRef
18.
Zurück zum Zitat Liang YH, Shao YY, Chen HM, Lai CL, Lin ZZ, Kuo RNC, Cheng AL, Yeh KH, Lai MS (2015) Young patients with colorectal cancer have increased risk of second primary cancers. Jpn J Clin Oncol 45:1029–1035CrossRef Liang YH, Shao YY, Chen HM, Lai CL, Lin ZZ, Kuo RNC, Cheng AL, Yeh KH, Lai MS (2015) Young patients with colorectal cancer have increased risk of second primary cancers. Jpn J Clin Oncol 45:1029–1035CrossRef
19.
Zurück zum Zitat Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC, Chen MH, Teng HW, Liu JH, Yen CC (2015) Incidence of second primary malignancies following colorectal cancer. Medicine (Baltimore) 94:7–11 Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC, Chen MH, Teng HW, Liu JH, Yen CC (2015) Incidence of second primary malignancies following colorectal cancer. Medicine (Baltimore) 94:7–11
20.
Zurück zum Zitat Ahmed F, Goodman MT, Kosary C, Ruiz B, Wu X-C, Chen VW, Correa CN (2006) Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975–2001. Cancer 107:1162–1171CrossRef Ahmed F, Goodman MT, Kosary C, Ruiz B, Wu X-C, Chen VW, Correa CN (2006) Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975–2001. Cancer 107:1162–1171CrossRef
21.
Zurück zum Zitat Phipps AI, Chan AT, Ogino S (2013) Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer 119:3140–3147CrossRef Phipps AI, Chan AT, Ogino S (2013) Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer 119:3140–3147CrossRef
22.
Zurück zum Zitat Guan X, Jin Y, Chen Y, Jiang Z, Liu Z, Zhao Z, Yan P, Wang G, Wang X (2015) The incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS ONE 10:1–18 Guan X, Jin Y, Chen Y, Jiang Z, Liu Z, Zhao Z, Yan P, Wang G, Wang X (2015) The incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS ONE 10:1–18
23.
Zurück zum Zitat Yang L, Li S, Lv M, Wu Y, Chen Z, Shen Y, Wang B, Chen L, Yi M, Yang J (2017) Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. Onco Targets Ther 10:1535–1548CrossRef Yang L, Li S, Lv M, Wu Y, Chen Z, Shen Y, Wang B, Chen L, Yi M, Yang J (2017) Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. Onco Targets Ther 10:1535–1548CrossRef
24.
Zurück zum Zitat Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG An Int J Obstet Gynaecol 114:1500–1509CrossRef Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG An Int J Obstet Gynaecol 114:1500–1509CrossRef
25.
Zurück zum Zitat Yun HR, Yi LJ, Cho YK, Park JH, Cho YB, Yun SH, Kim HC, Chun HK, Lee WY (2009) Double primary malignancy in colorectal cancer patients - MSI is the useful marker for predicting double primary tumors. Int J Colorectal Dis 24:369–375CrossRef Yun HR, Yi LJ, Cho YK, Park JH, Cho YB, Yun SH, Kim HC, Chun HK, Lee WY (2009) Double primary malignancy in colorectal cancer patients - MSI is the useful marker for predicting double primary tumors. Int J Colorectal Dis 24:369–375CrossRef
26.
Zurück zum Zitat Overman MJ, Ernstoff MS, Morse MA (2018) Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management Overman MJ, Ernstoff MS, Morse MA (2018) Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management
27.
Zurück zum Zitat Moreira L, Balaguer F, Lindor N, De La Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, De Leon MP, Rustgi AK, Castells A (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA - J Am Med Assoc 308:1555–1565CrossRef Moreira L, Balaguer F, Lindor N, De La Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, De Leon MP, Rustgi AK, Castells A (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA - J Am Med Assoc 308:1555–1565CrossRef
28.
Zurück zum Zitat Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284–296CrossRef Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284–296CrossRef
30.
Zurück zum Zitat Bucksch K, Zachariae S, Aretz S, Büttner R, Holinski-Feder E, Holzapfel S, Hüneburg R, Kloor M, Von Knebel Doeberitz M, Morak M, Möslein G, Nattermann J, Perne C, Rahner N, Schmiegel W, Schulmann K, Steinke-Lange V, Strassburg CP, Vangala DB, Weitz J, Loeffler M, Engel C (2020) Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: A prospective cohort study. BMC Cancer 20:1–11CrossRef Bucksch K, Zachariae S, Aretz S, Büttner R, Holinski-Feder E, Holzapfel S, Hüneburg R, Kloor M, Von Knebel Doeberitz M, Morak M, Möslein G, Nattermann J, Perne C, Rahner N, Schmiegel W, Schulmann K, Steinke-Lange V, Strassburg CP, Vangala DB, Weitz J, Loeffler M, Engel C (2020) Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: A prospective cohort study. BMC Cancer 20:1–11CrossRef
32.
Zurück zum Zitat Segelman J, Floter-Radestad A, Hellborg H, Sjovall A, Martling A (2010) Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg 97:1704–1709CrossRef Segelman J, Floter-Radestad A, Hellborg H, Sjovall A, Martling A (2010) Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg 97:1704–1709CrossRef
34.
Zurück zum Zitat Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149:97–101CrossRef Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149:97–101CrossRef
35.
Zurück zum Zitat Jiang R, Tang J, Cheng X, Zang RY (2008) Surgical treatment for patients with different origins of Krukenberg tumors : outcomes and prognostic factors *. Eur J Surg Oncol 35:92–97CrossRef Jiang R, Tang J, Cheng X, Zang RY (2008) Surgical treatment for patients with different origins of Krukenberg tumors : outcomes and prognostic factors *. Eur J Surg Oncol 35:92–97CrossRef
36.
Zurück zum Zitat Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, Holm T, Harris CC, Link KH, Kornmann M (2018) Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci 19:1–24CrossRef Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, Holm T, Harris CC, Link KH, Kornmann M (2018) Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci 19:1–24CrossRef
37.
Zurück zum Zitat Lehrer S, Green S, Rosenzweig KE (2016) Reduced ovarian cancer incidence in women exposed to low dose ionizing background radiation or radiation to the ovaries after treatment for breast cancer or rectosigmoid cancer. Asian Pac J Cancer Prev 17:2979–2982PubMed Lehrer S, Green S, Rosenzweig KE (2016) Reduced ovarian cancer incidence in women exposed to low dose ionizing background radiation or radiation to the ovaries after treatment for breast cancer or rectosigmoid cancer. Asian Pac J Cancer Prev 17:2979–2982PubMed
38.
Zurück zum Zitat Csaba G (2018) Hormesis and immunity: a review. Acta Microbiol Immunol Hung 66:155–168CrossRef Csaba G (2018) Hormesis and immunity: a review. Acta Microbiol Immunol Hung 66:155–168CrossRef
Metadaten
Titel
Primary ovarian cancer after colorectal cancer: a Dutch nationwide population-based study
verfasst von
R. van der Meer
I. H. J. T. de Hingh
S. F. P. J. Coppus
F. N. van Erning
R. M. H. Roumen
Publikationsdatum
13.06.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 7/2022
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-022-04184-w

Weitere Artikel der Ausgabe 7/2022

International Journal of Colorectal Disease 7/2022 Zur Ausgabe

Ist die Spülung bei Bohrlochtrepanation verzichtbar?

19.06.2024 Subduralhämatom Nachrichten

Wird ein chronisches Subduralhämatom per Bohrlochtrepanation entfernt, scheint eine subdurale Ausspülung mehr Vor- als Nachteile zu haben. Das legen Ergebnisse einer finnischen Studie nahe.

Was eine zu kleine Klappe für die Langzeitprognose bedeutet

18.06.2024 Aortenklappenersatz Nachrichten

Stellt sich nach der Implantation eines biologischen Aortenklappenersatzes die Prothese als zu klein für den Patienten heraus, hat das offenbar nur geringe Auswirkungen auf Langzeitüberleben und Reoperationsrisiko; zumindest solange die effektive Öffnungsfläche über 0,65 cm2/m2 liegt.

Antibiotika nach Appendektomie: Ist kürzer besser?

18.06.2024 Appendizitis Nachrichten

Nach einer Appendektomie wegen komplizierter Appendizitis scheint eine maximal dreitägige Antibiotikabehandlung hinreichend vor Komplikationen wie intraabdominellen Abszessen und Wundinfektionen zu schützen.

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.